Amyris (AMRS) Misses Q1 EPS by 7c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. ORCL
2. META
3. SPY
4. ANT
5. CART
6. FFAI
7. TSLA
8. FFR
9. XNCR
10. AZN

Go back to Amyris (AMRS) Misses Q1 EPS by 7c

AMYRIS, INC. REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS

May 10, 2022 8:00 AM EDT

Record consumer revenue of $34.6 million increased 121% compared to Q1 2021Barra Bonita commissioning on track to commence ingredients production in Q2

EMERYVILLE, Calif., May 10, 2022 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-MarketTM technology platform, today announced financial results for the first quarter ended March 31, 2022.

"We continued to advance our growth roadmap, delivering 75% core revenue growth and growing consumer... More